Vascualr JClaesson-Welsh L et al. Article CAS Google Scholar Ferrara, N. Br J Cancer 79—

Angiogenesis and vascular growth -

Thus, they can initiate cell signaling when ligand binding causes a dimerization that initiates phosphorylation on key tyrosines. Another major contributor to angiogenesis is matrix metalloproteinase MMP. MMPs help degrade the proteins that keep the vessel walls solid.

This proteolysis allows the endothelial cells to escape into the interstitial matrix as seen in sprouting angiogenesis. Inhibition of MMPs prevents the formation of new capillaries. Delta-like ligand 4 Dll4 is a protein with a negative regulatory effect on angiogenesis.

There have been many studies conducted that have served to determine consequences of the Delta-like Ligand 4. One study in particular evaluated the effects of Dll4 on tumor vascularity and growth.

The VEGF pathway is vital to the development of vasculature that in turn, helps the tumors to grow. The combined blockade of VEGF and Dll4 results in the inhibition of tumor progression and angiogenesis throughout the tumor.

This is due to the hindrance of signaling in endothelial cell signaling which cuts off the proliferation and sprouting of these endothelial cells. With this inhibition, the cells do not uncontrollably grow, therefore, the cancer is stopped at this point.

if the blockade, however, were to be lifted, the cells would begin their proliferation once again. Class 3 semaphorins SEMA3s regulate angiogenesis by modulating endothelial cell adhesion, migration, proliferation, survival and the recruitment of pericytes.

An angiogenesis inhibitor can be endogenous or come from outside as drug or a dietary component. Angiogenesis may be a target for combating diseases such as heart disease characterized by either poor vascularisation or abnormal vasculature.

The presence of blood vessels where there should be none may affect the mechanical properties of a tissue, increasing the likelihood of failure. The absence of blood vessels in a repairing or otherwise metabolically active tissue may inhibit repair or other essential functions. Several diseases, such as ischemic chronic wounds , are the result of failure or insufficient blood vessel formation and may be treated by a local expansion of blood vessels, thus bringing new nutrients to the site, facilitating repair.

Other diseases, such as age-related macular degeneration , may be created by a local expansion of blood vessels, interfering with normal physiological processes. The modern clinical application of the principle of angiogenesis can be divided into two main areas: anti-angiogenic therapies, which angiogenic research began with, and pro-angiogenic therapies.

Whereas anti-angiogenic therapies are being employed to fight cancer and malignancies, [37] [38] which require an abundance of oxygen and nutrients to proliferate, pro-angiogenic therapies are being explored as options to treat cardiovascular diseases , the number one cause of death in the Western world.

One of the first applications of pro-angiogenic methods in humans was a German trial using fibroblast growth factor 1 FGF-1 for the treatment of coronary artery disease.

Regarding the mechanism of action , pro-angiogenic methods can be differentiated into three main categories: gene therapy , targeting genes of interest for amplification or inhibition; protein replacement therapy , which primarily manipulates angiogenic growth factors like FGF-1 or vascular endothelial growth factor , VEGF; and cell-based therapies, which involve the implantation of specific cell types.

There are still serious, unsolved problems related to gene therapy. Difficulties include effective integration of the therapeutic genes into the genome of target cells, reducing the risk of an undesired immune response, potential toxicity, immunogenicity , inflammatory responses, and oncogenesis related to the viral vectors used in implanting genes and the sheer complexity of the genetic basis of angiogenesis.

The most commonly occurring disorders in humans, such as heart disease, high blood pressure, diabetes and Alzheimer's disease , are most likely caused by the combined effects of variations in many genes, and, thus, injecting a single gene may not be significantly beneficial in such diseases.

By contrast, pro-angiogenic protein therapy uses well-defined, precisely structured proteins, with previously defined optimal doses of the individual protein for disease states, and with well-known biological effects.

Oral, intravenous, intra-arterial, or intramuscular routes of protein administration are not always as effective, as the therapeutic protein may be metabolized or cleared before it can enter the target tissue.

Cell-based pro-angiogenic therapies are still early stages of research, with many open questions regarding best cell types and dosages to use. Cancer cells are cells that have lost their ability to divide in a controlled fashion.

A malignant tumor consists of a population of rapidly dividing and growing cancer cells that progressively accrues mutations. However, tumors need a dedicated blood supply to provide the oxygen and other essential nutrients they require in order to grow beyond a certain size generally 1—2 mm 3.

Tumors induce blood vessel growth angiogenesis by secreting various growth factors e. VEGF and proteins. Growth factors such as bFGF and VEGF can induce capillary growth into the tumor, which some researchers suspect supply required nutrients, allowing for tumor expansion.

Unlike normal blood vessels, tumor blood vessels are dilated with an irregular shape. In either case, angiogenesis is a necessary and required step for transition from a small harmless cluster of cells, often said to be about the size of the metal ball at the end of a ball-point pen, to a large tumor.

Angiogenesis is also required for the spread of a tumor, or metastasis. Evidence now suggests the blood vessel in a given solid tumor may, in fact, be mosaic vessels, composed of endothelial cells and tumor cells.

Endothelial cells have long been considered genetically more stable than cancer cells. This genomic stability confers an advantage to targeting endothelial cells using antiangiogenic therapy, compared to chemotherapy directed at cancer cells, which rapidly mutate and acquire drug resistance to treatment.

For this reason, endothelial cells are thought to be an ideal target for therapies directed against them. The mechanism of blood vessel formation by angiogenesis is initiated by the spontaneous dividing of tumor cells due to a mutation. Angiogenic stimulators are then released by the tumor cells.

These then travel to already established, nearby blood vessels and activates their endothelial cell receptors.

This induces a release of proteolytic enzymes from the vasculature. These enzymes target a particular point on the blood vessel and cause a pore to form. This is the point where the new blood vessel will grow from.

The reason tumour cells need a blood supply is because they cannot grow any more than millimeters in diameter without an established blood supply which is equivalent to about cells. Angiogenesis represents an excellent therapeutic target for the treatment of cardiovascular disease. It is a potent, physiological process that underlies the natural manner in which our bodies respond to a diminution of blood supply to vital organs, namely neoangiogenesis : the production of new collateral vessels to overcome the ischemic insult.

Reproducible and credible successes in these early animal studies led to high enthusiasm that this new therapeutic approach could be rapidly translated to a clinical benefit for millions of patients in the Western world with these disorders.

A decade of clinical testing both gene- and protein-based therapies designed to stimulate angiogenesis in underperfused tissues and organs, however, has led from one disappointment to another.

Although all of these preclinical readouts, which offered great promise for the transition of angiogenesis therapy from animals to humans, were in one fashion or another, incorporated into early stage clinical trials, the FDA has, to date , insisted that the primary endpoint for approval of an angiogenic agent must be an improvement in exercise performance of treated patients.

These failures suggested that either these are the wrong molecular targets to induce neovascularization, that they can only be effectively used if formulated and administered correctly, or that their presentation in the context of the overall cellular microenvironment may play a vital role in their utility.

It may be necessary to present these proteins in a way that mimics natural signaling events, including the concentration , spatial and temporal profiles, and their simultaneous or sequential presentation with other appropriate factors. Angiogenesis is generally associated with aerobic exercise and endurance exercise.

While arteriogenesis produces network changes that allow for a large increase in the amount of total flow in a network, angiogenesis causes changes that allow for greater nutrient delivery over a long period of time.

Capillaries are designed to provide maximum nutrient delivery efficiency, so an increase in the number of capillaries allows the network to deliver more nutrients in the same amount of time.

A greater number of capillaries also allows for greater oxygen exchange in the network. This is vitally important to endurance training, because it allows a person to continue training for an extended period of time. However, no experimental evidence suggests that increased capillarity is required in endurance exercise to increase the maximum oxygen delivery.

Overexpression of VEGF causes increased permeability in blood vessels in addition to stimulating angiogenesis. In wet macular degeneration , VEGF causes proliferation of capillaries into the retina.

Since the increase in angiogenesis also causes edema , blood and other retinal fluids leak into the retina , causing loss of vision.

Anti-angiogenic drugs targeting the VEGF pathways are now used successfully to treat this type of macular degeneration. Angiogenesis of vessels from the host body into an implanted tissue engineered constructs is essential. Successful integration is often dependent on thorough vascularisation of the construct as it provides oxygen and nutrients and prevents necrosis in the central areas of the implant.

The first report of angiogenesis can be traced back to the book A treatise on the blood, inflammation, and gun-shot wounds published in , where Scottish anatomist John Hunter 's research findings were compiled.

In his study, Hunter observed the growth process of new blood vessels in rabbits. However, he did not coin the term "Angiogenesis," which is now widely used by scholars. Hunter also erroneously attributed the growth process of new blood vessels to the effect of an innate vital principle within the blood.

The term "angiogenesis" is believed to have emerged not until the s. The inception of modern angiogenesis research is marked by Judah Folkman's report on the pivotal role of angiogenesis in tumor growth. Quantifying vasculature parameters such as microvascular density has various complications due to preferential staining or limited representation of tissues by histological sections.

Recent research has shown complete 3D reconstruction of tumor vascular structure and quantification of vessel structures in whole tumors in animal models.

Contents move to sidebar hide. Article Talk. Read Edit View history. Tools Tools. What links here Related changes Upload file Special pages Permanent link Page information Cite this page Get shortened URL Download QR code Wikidata item. Download as PDF Printable version.

Protein tyrosine kinase expressed in glomeruli and cultured glomerular cells: FLT-1 and VEGF expression in renal mesangial cells. Ahmed A , Li XF, Dunk C et al. Co-localisation of vascular endothelial growth factor and its receptor in human placenta.

Growth Factors. Keyt BA , Nguyen HV, Berleau LT et al. Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. Sawano A , Takahashi T, Yamaguchi S et al.

Gitay-Goren H , Cohen T, Tessler S et al. Selective binding of VEGF to one of the three vascular endothelial growth factor receptors of vascular endothelial cells.

Wilting J , Birkenhager R, Eichmann A et al. VEGF induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane.

Dev Biol. Davis-Smyth TH , Park J, Presta LG et al. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade. Kendall RL , Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor.

Kendall RL , Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

Hornig C , Barleon B, Ahmad S et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids.

Vuorela P , Helske S, Hornig C et al. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia. Obstet Gynecol. Terman BI , Jani-Sait S, Carrion ME et al.

The KDR gene maps to human chromosome 4q Cytogenet Cell Genet. Terman BI , Carrion ME, Rasmussen BA et al. Identification of a new endothelial growth factor receptor tyrosine kinase. Millauer B , Wizigmann-Voos S, Schnurch H et al.

High affinity VEGF binding and developmental expression flk-1 as a major regulator of vasculogenesis and angiogenesis. Terman BI , Dougher-Vermazen M, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.

Khaliq A , Li XF, Shams M et al. Localisation of placenta growth factor PIGF in human term placenta. Thieme H , Aiello LP, Takagi H et al.

Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells.

Vuckovic M , Ponting J, Terman BI et al. Expression ofthe vascular endothelial growth factor receptor, KDR, in human placenta. J Anatomy. Katoh O , Tauchi H, Kawaishi K et al.

Expression of the vascular endothelial growth factor VEGF receptor gene, KDR, in hematopoietic cells and inhibitory effect ofVEGF on apoptotic cell death caused by ionizing radiation.

Yang XJ , Cepko CL. Flk-1, a receptor for vascular endothelial growth factor VEGF , is expressed by retinalprogenitor cells. J Neurosci. Waltenberger J , Claesson-Welsh L et al. Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor.

Millauer B , Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumour types in vivo. Galland F , Karamysheva A, Mattei MG et al. Chromosomal localization of Flt-4, a novel receptor-type tyrosine gene.

Hewett PW , Murray JC. Coexpression-1, flt-4 and KDRin freshly isolated and cultured human endothelial cells. Soker S , Takashima S, Miao HQ et al. Neuropilin-1 is expressed by endothelial and tumour cells as an isoform-specific receptor for vascular endothelial growth factor. Kitsukawa T , Shimizu M, Sanbo M et al.

Adamis AP , Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularisation in non-human primate. Arch Ophthalmol. Aiello LP , Pierce EA, Foley ED et al.

Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor VEGF using soluble VEGF-receptor chimeric proteins. Proc Natl Sci USA. Borgi E , Schatteman G, Wu T et al.

Hypoxia-inducedparacrine regulation of vascular endothelial growth factor receptor expression. Williams B.

Deroanne CF , Hajitou A, Calberg-Bacq CM et al. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression.

Finkenzeller G , Sparacio A, Technau A et al. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression. Ryuto M , Ono M, Izumi H et al.

Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Stavri GT , Zachary IC, Baskerville PA et al. Basic fibroblast growth factor upregulates the expression of vascularendothelial growth factor in vascular smooth muscle cells.

Synergistic interaction with hypoxia. Williams B , Baker AQ, Gallacher B et al. Angio-tensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells.

Frank S , Hubner G, Breier G et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. Goad DL , Rubin J, Wang H et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I.

Cohen T , Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. Keck PJ , Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF. Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.

Matsumoto K , Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Dumont DJ , Gradwohl G, Fong GH et al. Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo.

Genes Dev. Shweiki D , Neeman M, Itin A et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implicationsfor tumor angiogenesis.

Forsythe JA , Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. Jiang BH , Semenza GL, Bauer C et al. Hypoxia-inducible factor 1 HIF-1 levels vary exponentially over a physiologically relevant range of O 2 tension.

Gerber HP , Condorelli F, Park J et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Sandner P , Wolf K, Bergmaier U et al. Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro. Kidney Int.

Hypoxia and cobalt stimulate vascular endothelial growth factor receptor gene expression in rats. Pflugers Arch. Shweiki D , Itin A, Neufeld G et al. Patterns of expressionof vascular endothelial growth factor VEGF and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.

Battegay EJ. Angiogenesis: mechanistic insight, neovascular diseases, and therapeutic prospects. J Mol Med. Gu JW , Adair TH. Hypoxia-induced expression of VEGF is reversible in myocardial vascular smooth muscle cells.

Klekamp JG , Jarzecka K, Perkett EA. Exposure to hyperoxia decreases the expression of vascular endothelial growth factor and its receptors in adults rat lungs. Yue X , Tomanek RJ. Alon T , Hemo I, Itin A et al. Vascular growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity.

Murohara T , Horowitz JR, Silver M et al. Ziche M , Morbidelli L, Choudhuri R et al. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis.

Miyazaki H , Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of angiogenesis. Tsurumi Y , Murohara T, Krasinski K et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Moncada S , Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology.

Pharmacol Rev. Konda S , Asano M, Matsuo K et al. Belgore FM , Lip GYH, Wadley M et al. Plasma levelsof vascular endothelial cell growth factor VEGF andits receptor sFlt-1 in haematological cancers: a comparison with breast cancer.

Am J Haematol. Kotch LE , Iyer NV, Laughner E et al. Defective vascularization of HIF-lalpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death. Sone H , Kawakami Y, Okuda Y et al. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulation by acute glucose deprivationin cultured bovine retinal pigmented epithelial cells.

Satake S , Kuzuya M, Miura H et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Chem.

Park SH , Kim KW, Lee YS et al. Int J Mol Med. Cha DR , Kim NH, Yoon JW et al. Role of vascular endothelial growth factor in diabetic nephropathy.

Kim NH , Jung HH, Cha DR et al. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol. Hoshi S , Nomoto Ki K, Kuromitsu J.

High glucose induced VEGF expression via PKC and ERK in glomerular podocytes. Aiello LP , Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders.

Breier G , Damert A, Plate KH et al. Angiogenesis in embryos and ischemic disease. Gale NW , Yancopoulos GD. Growth factors acting viaendothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Gene Dev. Carmeliet P , Ferrera V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Ferrara N , Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.

Molica S , Vitelli G, Levato D et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia. Br J Haematol. Zhang H-T , Craft P, Scott PAE et al. Enhancement of tumour growth and vascular dentistry by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells.

J Natl Cancer Inst. Relf M , LeJeune S, Scott PA et al. Expression of the angiogenic factors VEGF, acidic and basic FGF, tumour growth factor beta-1, PDGF, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Suzuki K , Hayashi N, Miyamoto Y et al. Viglietto G , Romano A, Maglione D et al. Neovascularisation in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not placenta-derived growth factor.

Viglietto G , Maglione D, Rambaldi M et al. Upregulation of vascular endothelial growth factor VEGF and down regulation of placenta growth factor PIGF associated with malignancy in human thyroid tumors and cell lines.

Tsurusaki T , Kanda S, Sakai H et al. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis.

Br J Cancer. Salven P , Lymboussaki A, Heikkila P et al. Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumours. Soker S , Fidder H, Neufeld G et al. Characterization of novel endothelial growth factor VEGF receptors ontumour cells that bind VEGF via exon 7-encoded domain.

Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. Blann AD , Li J-L, Kumar S. Increased VEGF in 13 children with Wilms' tumour falls after surgery but rising levels predict mortality.

Cancer Lett. Ausprunk DH , Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis. Lauer G , Sollberg S, Cole M et al. Expression and proteolysis of vascular endothelial growth factor increased in chronic wounds.

J Invest Dermatol. Mochida S , Ishikawa K, Inao M et al. Detmar M , Brown LF, Berse B et al. J Invest Derm. Lee SS , Joo YS, Kim WU et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis.

Clin Exp Rheumatol. Robak E , Wozniacka A, Sysa-Jedrzejowska A et al. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity.

EurCytokine Netw. Mohle R , Green D, Moore MAS et al. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets.

Fava RA , Olsen NJ, Spencer-Green G et al. Nagashima M , Yoshino S, Ishiwata T et al. Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol.

Latour F , Zabraniecki L, Fromer C et al. Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction? A clinical, radiological and pathological study in 12 patients monitored for 10 years. Joint Bone Spine. Paavonen K , Mandelin J, Partanen T et al.

Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.

Li J , Brown LF, Hibberd MG et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Hausner EA , Orsini JA, Foster LL et al.

Vascular endothelial growth factor in porcine coronary arteries followingballoon angioplasty. J Invest Surg. Ruef J , Hu ZY, Yin LY et al. Induction of vascular endothelial growth factor in balloon-injured baboon arteries.

A novel role for reactive oxygen species in atherosclerosis. Harada K , Friedman M, Lopez JJ et al. Vascular endothelial growth factor administration in chronic myocardial ischaemia.

Lee SH , Wolf PL, Escudero et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. Inoue M , Itoh H, Ueda M et al. Vascular endothelial growth factor VEGF expression in human coronary atherosclerotic lesions.

Possible pathophysiological significance of VEGF in the progression of atherosclerosis. Chen YX , Nakashima Y, Tenaka K et al. Couffinhal C , Kearney M, Witzenbichler B et al. Bobryshev YV , Farnsworth AE, Lord RS. Expression of vascular endothelial growth factor in aortocoronary saphenous vein bypass grafts.

Cardiovasc Surg. Fleisch M , Billinger M, Eberli FR et al. Physiologically assessed coronary collateral flow and intra-coronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease.

Burton PBJ , Owen VJ, Hafizi S et al. Hojo Y , Ikeda U, Zhu Y et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction. J Am Coll Cardiol. Roller RE , Renner W, Tischler R et al.

Vascular endothelial growth factor in plasma of patients undergoing peripheral angioplasty. O'Brien KD , Chait A. The biology of the artery wall in atherogenesis.

Med Clin North Am. Barger AC , Beeuwkes R, Lainey LL et al. Hypothesis: vasa vasorum and noevascularisation of human coronaryarteries. A possible role in the Pathophysiology of atherosclerosis. Reyer JA , Myers PC, Appleberg M.

Carotid intraplaque hemorrhage: the significance of neovascularity. J Vasc Surg. Henry TD. Therapeutic angiogenesis. Br Med J.

Angiogenic therapy of the heart. Angiogenic therapy of the ischaemic limb. Helisch A , Ware JA. Therapeutic angiogenesis in ischemic heart disease. Kornowski R , Fuchs S, Leon MB et al. Delivery strategies to achieve therapeutic myocardial angiogenesis. Henry TD , Rocha-Singh K, Isner JM et al.

Intra-coronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. Rosengart TK , Lee LY, Patel SR et al.

Phase 1 asessment of direct intramyocardial administration of an adenovirisexpressing VEGF cDNA to individuals with clinically significant severe coronary artery disease.

Isner JM , Pieczek A, Schainfeld R et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF in paitent with ischaemic limb. Celletti FL , Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression.

Brenchley PEC. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis. Braybrooke JP , O'Byrne K, Propper DJ et al. A phase II study of Razoxane, an anti-angiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Clin Cancer Res. Lederman RJ , Mendelsohn FO, Anderson RD et al. for the TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblastic growth factor-2 for intermittent claudication the TRAFFIC study : a randomized trial.

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide.

Sign In or Create an Account. Advertisement intended for healthcare professionals. Navbar Search Filter European Heart Journal This issue ESC Publications Cardiovascular Medicine Books Journals Oxford Academic Mobile Enter search term Search. Issues More Content Advance Articles Editor's Choice Braunwald's Corner ESC Guidelines EHJ Dialogues Issue a Glance Podcasts CardioPulse Weekly Journal Scan European Heart Journal Supplements Year in Cardiovascular Medicine Asia in EHJ Most Cited Articles ESC Content Collections Submit Author Guidelines Submission Site Why publish with EHJ?

Therapeutic angiogenesis aims to restore blood flow to ischaemic tissue by stimulating the growth of new blood vessels through the local delivery of angiogenic factors, and may thus be an attractive treatment alternative for these patients.

Angiogenesis is a complex process and the growth of normal, stable and functional vasculature depends on the coordinated interplay of different cell types and growth factors.

Vascular endothelial growth factor-A VEGF is the fundamental regulator of vascular growth and the key target of therapeutic angiogenesis approaches. However, first-generation clinical trials of VEGF gene therapy have been disappointing, and a clear clinical benefit has yet to be established.

In particular, VEGF delivery a appears to have a very limited therapeutic window in vivo: low doses are safe but mostly inefficient, whereas higher doses become rapidly unsafe; and b requires a sustained expression in vivo of at least about four weeks to achieve stable vessels that persist after cessation of the angiogenic stimulus.

Department Angiogenwsis Medical Biochemistry and Angiogenesis and vascular growth Biomedical Vasuclar, University of Uppsala, Angikgenesis, Sweden. Angiogenesis and vascular growth can also search for this editor Closed-loop glucose monitoring PubMed Google Scholar. This is a preview of subscription content, log in via an institution to check for access. Lena Claesson-Welsh. Book Title : Vascular Growth Factors and Angiogenesis. Editors : Lena Claesson-Welsh. Series Title : Current Topics in Microbiology and Immunology.

Video

Angiogenesis Angiogenesis and vascular growth KimTatiana V. Byzova; Oxidative stress in angiogenesis and vascular disease. Blood ; 5 : — Angipgenesis the damaging effect on tissues Angiogemesis a Body cleanse for digestion concentration, it has been Growyh established that oxidative stress plays a positive role during angiogenesis. The ROS can be generated either endogenously, through mitochondrial electron transport chain reactions and nicotinamide adenine dinucleotide phosphate oxidase, or exogenously, resulting from exposure to environmental agents, such as ultraviolet or ionizing radiation. In many conditions, ROS promotes angiogenesis, either directly or via the generation of active oxidation products, including peroxidized lipids.

Angiogenesis and vascular growth -

Report of the Second International Workshop on Human Chromosome 6. Houck KA , Ferrara N, Winer J et al. The vascular endothelial growth factor family: identification of a fourth molecular species and characterisation of alternative splicing of RNA.

Tischer E , Mitchell R, Hartmann T et al. The human gene for vascular endothelial growth factor: multiple protein forms are encoded through alternative exon splicing.

Park JE , Keller GA, Ferrara N. The vascular endothelial growth factor VEGF isoforms: differential deposition into the sub-epithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF. Mol Biol Cell. Houck KA , Leung DW, Rowland AM et al.

Dual regulationof vascular endothelial growth factor bioavailability bygenetic and proteolytic mechanisms. Keyt BA , Berleau LT, Nguyen HV et al. The carboxyl-terminal domain — of vascular endothelial growth factoris critical for its mitogenic potency.

Blann AD , Belgore FM, McCollum CN et al. Vascular endothelial growth factor and its receptor Flt-1 in the plasma of patients with coronary and peripheral atherosclerosis and type II diabetes. Clin Sci. Seko Y , Imai Y, Suzuki S et al.

Serum levels of vascular endothelial growth factor in patients with acute myocardial infarction undergoing reperfusion therapy. Lip PL , Belgore FM, Blann AD. Plasma vascular endothelial growth factor and soluble VEGF receptor Flt-1 in prolifer-ative retinopathy: a pilot study of the relationship toendothelial dysfunction and laser treatment.

Invest Ophthalmol Vis Sci. Webb NJ , Bottomley MJ, Watson CJ et al. Vascular endothelial growth factor VEGF is released from plateletsduring blood clotting: implications for the measurement of circulating VEGF levels in clinical disease.

Olofsson B , Pajusola K, Kaipainen A et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Olofsson B , Pajusola K, von Euler G et al.

Genomic organization of the mouse and human genes for vascular endothelial growth factor B VEGF-B and characterization of a second splice isoform. Joukov V , Kaipainen A, Jeltsch M et al. Vascular endothelial growth factors VEGF-B and VEGF-C. J Cell Physiol. Chilov D , Kukk E, Taira S et al.

Genomic organisation of human and mouse genes for vascular endothelial growth factor C. Kukk E , Lymboussaki ST, Kaipaninen A et al.

VEGF-C receptor binding pattern of expression with VEGFR-3 suggestsa role in lymphatic development. Wartiovaara U , Salven P, Mikkola H et al. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation.

Fitz LJ , Morris JC, Towler P et al. Kaipainen A , Korhonen J, Mustonen T et al. Expression of the fms-like tyrosine kinase 4 gene becomes restricted to lymphatic endothelium during development.

Kaipainen A , Korhonen J, Pajusola K et al. The related Flt-4, Flt-1, and KDR receptor tyrosine kinases show distinct expression patterns in human foetal endothelial cells. J Exp Med. Witzenbichler B , Asahara T, Murohara T et al.

Aase K , Lymboussaki A, Kaipainen A et al. Localisation of VEGF-B in the mouse embryo suggests a paracrine role of the growth factor in the developing vasculature. Dev Dyn. Yamada Y , Nezu J, Shimane M et al. Molecular cloning of a novel vascular endothelial growth factor, VEGF-D.

Achen MG , Jeltsch M, Kukk E et al. Vascular endothelial growth factor D VEGF-D is a ligand for tyrosine kinases VEGF receptor 2 Flk1 and VEGF receptor 3 Flt Orlandini M , Marconcini L, Ferruzzi R et al.

Karkkainen MJ , Petrova TV. Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis. Staker SA , Caesar C, Baldwin ME et al. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Meyer M , Clauss M, Lepple-Wienhues A et al.

A novel vascular endothelial growth factor encoded by Orf virus, VEGF-E mediates angiogenesis via signalling through VEGFR-2 KDR but not VEGFR-1 Flt-1 receptor kinases.

Lyttle DJ , Fraser KM, Flemings SB et al. Homologs of vascular endothelial growth factor are encoded by the poxvirus Orf virus. J Virol. Savory LJ , Stacker SA, Flemming SB et al. Viral vascular endothelial growth factor plays a critical role in Orf virus infection.

Maglione D , Guerriero V, Viglietto G et al. Isolation of a human placenta cDNA coding for a protein related to the vascular permeability factor. Placenta growth factor: identification and characterization of a novel isoform generated by RNA alternative splicing. Weindel K , Moringlane JR, Marme D et al.

Takahashi A , Sasaki H, Kim SJ et al. Marked increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated angiogenesis. Cancer Res. Cao Y , Linden P, Shima D et al.

Davis S , Aldrich T, Jones PF et al. Isolation of angiopoietin-1, a ligand for the angiogenic TIE-2 receptor, by secretion-trap expression cloning. Maisonpierre PC , Suri C, Jones PF et al. Angiopoietin-2, a natural antagonist for TIE2 that disrupts in vivo angiogenesis.

Valenzuela DM , Griffith JA, Rojass J et al. Angiopoietin 3 and 4: diverging gene counterparts in mice and humans. Koblizek TI , Weiss C, Yancopoulos GD et al.

Angiopoietin-1 induces sprouting angiogenesis in vitro. Curr Biol. Sato TN , Tozawa Y, Deutsch U et al. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation. Suri C , Jones PF, Patan S et al. Requisite role of angiopoietin-1, a ligand for the TIE-2 receptor, during embryonic angiogenesis.

Vikkula M , Boon LM, Carraway KL et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Matthews W , Jordan CT, Gavin M et al. A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close geneticlinkage to c-kit.

Proc Natl Acad Sci. Park M , Lee ST. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site.

De-Vries C , Escobedo JA, Ueno H et al. The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor. Shibuya M , Yamaguchi S, Yamame A et al. Nucleotide sequence and expression of novel human receptors-type tyrosine kinase gene flt-1 closely related to fms family.

Charnock-Jones D , Sharkey A, Boocock C et al. Vascular endothelial growth factor receptor localization and activation in human trophoblast and choriocarcinoma cells. Simon M , Grone HJ, Johren O et al. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and adult kidney.

Pajusola K , Aprelikova O, Korhonen J et al. Flt-4 receptor tyrosine kinase contains seven immunoglobulin-like loops and is expressed in multiple human tissues and cell lines.

Rosnet O , Mattei MG, Marchetto S et al. Isolation and chromosomal localisation of a novel FMS-like tyrosinekinase gene. Barleon B , Sozzani S, Zhou D et al. Migration of human monocytes in response to vascular endothelial growthfactor VEGF is mediated via the VEGF receptor flt Takahashi T , Shiraswa T, Miyake K et al.

Protein tyrosine kinase expressed in glomeruli and cultured glomerular cells: FLT-1 and VEGF expression in renal mesangial cells. Ahmed A , Li XF, Dunk C et al.

Co-localisation of vascular endothelial growth factor and its receptor in human placenta. Growth Factors. Keyt BA , Nguyen HV, Berleau LT et al.

Identification of vascular endothelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. Sawano A , Takahashi T, Yamaguchi S et al.

Gitay-Goren H , Cohen T, Tessler S et al. Selective binding of VEGF to one of the three vascular endothelial growth factor receptors of vascular endothelial cells. Wilting J , Birkenhager R, Eichmann A et al.

VEGF induces proliferation of vascular endothelial cells and expression of flk-1 without affecting lymphatic vessels of chorioallantoic membrane.

Dev Biol. Davis-Smyth TH , Park J, Presta LG et al. The second immunoglobulin-like domain of the VEGF tyrosine kinase receptor Flt-1 determines ligand binding and may initiate a signal transduction cascade.

Kendall RL , Thomas KA. Inhibition of vascular endothelial growth factor activity by an endogenously encoded soluble receptor. Kendall RL , Wang G, Thomas KA. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR.

Hornig C , Barleon B, Ahmad S et al. Release and complex formation of soluble VEGFR-1 from endothelial cells and biological fluids. Vuorela P , Helske S, Hornig C et al. Amniotic fluid-soluble vascular endothelial growth factor receptor-1 in preeclampsia.

Obstet Gynecol. Terman BI , Jani-Sait S, Carrion ME et al. The KDR gene maps to human chromosome 4q Cytogenet Cell Genet. Terman BI , Carrion ME, Rasmussen BA et al. Identification of a new endothelial growth factor receptor tyrosine kinase.

Millauer B , Wizigmann-Voos S, Schnurch H et al. High affinity VEGF binding and developmental expression flk-1 as a major regulator of vasculogenesis and angiogenesis. Terman BI , Dougher-Vermazen M, Carrion ME et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.

Khaliq A , Li XF, Shams M et al. Localisation of placenta growth factor PIGF in human term placenta. Thieme H , Aiello LP, Takagi H et al.

Comparative analysis of vascular endothelial growth factor receptors on retinal and aortic vascular endothelial cells. Vuckovic M , Ponting J, Terman BI et al.

Expression ofthe vascular endothelial growth factor receptor, KDR, in human placenta. J Anatomy. Katoh O , Tauchi H, Kawaishi K et al. Expression of the vascular endothelial growth factor VEGF receptor gene, KDR, in hematopoietic cells and inhibitory effect ofVEGF on apoptotic cell death caused by ionizing radiation.

Yang XJ , Cepko CL. Flk-1, a receptor for vascular endothelial growth factor VEGF , is expressed by retinalprogenitor cells. J Neurosci. Waltenberger J , Claesson-Welsh L et al.

Different signal transduction properties of KDR and Flt1, two receptors for vascular endothelial growth factor. Millauer B , Longhi MP, Plate KH et al. Dominant-negative inhibition of Flk-1 suppresses the growth of many tumour types in vivo.

Galland F , Karamysheva A, Mattei MG et al. Chromosomal localization of Flt-4, a novel receptor-type tyrosine gene.

Hewett PW , Murray JC. Coexpression-1, flt-4 and KDRin freshly isolated and cultured human endothelial cells. Soker S , Takashima S, Miao HQ et al.

Neuropilin-1 is expressed by endothelial and tumour cells as an isoform-specific receptor for vascular endothelial growth factor.

Kitsukawa T , Shimizu M, Sanbo M et al. Adamis AP , Shima DT, Tolentino MJ et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularisation in non-human primate.

Arch Ophthalmol. Aiello LP , Pierce EA, Foley ED et al. Suppression of retinal neovascularisation in vivo by inhibition of vascular endothelial growth factor VEGF using soluble VEGF-receptor chimeric proteins.

Proc Natl Sci USA. Borgi E , Schatteman G, Wu T et al. Hypoxia-inducedparacrine regulation of vascular endothelial growth factor receptor expression. Williams B. Deroanne CF , Hajitou A, Calberg-Bacq CM et al.

Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Finkenzeller G , Sparacio A, Technau A et al. Sp1 recognition sites in the proximal promoter of the human vascular endothelial growth factor gene are essential for platelet-derived growth factor-induced gene expression.

Ryuto M , Ono M, Izumi H et al. Induction of vascular endothelial growth factor by tumor necrosis factor alpha in human glioma cells. Stavri GT , Zachary IC, Baskerville PA et al. Basic fibroblast growth factor upregulates the expression of vascularendothelial growth factor in vascular smooth muscle cells.

Synergistic interaction with hypoxia. Williams B , Baker AQ, Gallacher B et al. Angio-tensin II increases vascular permeability factor gene expression by human vascular smooth muscle cells.

Frank S , Hubner G, Breier G et al. Regulation of vascular endothelial growth factor expression in cultured keratinocytes. Implications for normal and impaired wound healing. Goad DL , Rubin J, Wang H et al. Enhanced expression of vascular endothelial growth factor in human SaOS-2 osteoblast-like cells and murine osteoblasts induced by insulin-like growth factor I.

Cohen T , Nahari D, Cerem LW et al. Interleukin 6 induces the expression of vascular endothelial growth factor. Keck PJ , Hauser SD, Krivi G et al. Vascular permeability factor, an endothelial cell mitogen related to PDGF.

Matsumoto K. Interleukin 10 inhibits vascular permeability factor release by peripheral blood mononuclear cells in patients with lipoid nephrosis.

Matsumoto K , Ohi H, Kanmatsuse K. Interleukin 10 and interleukin 13 synergize to inhibit vascular permeability factor release by peripheral blood mononuclear cells from patients with lipoid nephrosis. Dumont DJ , Gradwohl G, Fong GH et al.

Dominant-negative and targeted null mutations in the endothelial receptor tyrosine kinase, tek, reveal a critical role in vasculogenesis of the embryo.

Genes Dev. Shweiki D , Neeman M, Itin A et al. Induction of vascular endothelial growth factor expression by hypoxia and by glucose deficiency in multicell spheroids: implicationsfor tumor angiogenesis.

Forsythe JA , Jiang BH, Iyer NV et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. Jiang BH , Semenza GL, Bauer C et al. Hypoxia-inducible factor 1 HIF-1 levels vary exponentially over a physiologically relevant range of O 2 tension.

Gerber HP , Condorelli F, Park J et al. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Sandner P , Wolf K, Bergmaier U et al. Induction of VEGF and VEGF receptor gene expression by hypoxia: divergent regulation in vivo and in vitro.

Kidney Int. Hypoxia and cobalt stimulate vascular endothelial growth factor receptor gene expression in rats.

Pflugers Arch. Shweiki D , Itin A, Neufeld G et al. Patterns of expressionof vascular endothelial growth factor VEGF and VEGF receptors in mice suggest a role in hormonally regulated angiogenesis.

Battegay EJ. Angiogenesis: mechanistic insight, neovascular diseases, and therapeutic prospects. J Mol Med. Gu JW , Adair TH. Hypoxia-induced expression of VEGF is reversible in myocardial vascular smooth muscle cells. Klekamp JG , Jarzecka K, Perkett EA.

Exposure to hyperoxia decreases the expression of vascular endothelial growth factor and its receptors in adults rat lungs.

Yue X , Tomanek RJ. Alon T , Hemo I, Itin A et al. Vascular growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Murohara T , Horowitz JR, Silver M et al. Ziche M , Morbidelli L, Choudhuri R et al.

Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis. Miyazaki H , Matsuoka H, Cooke JP et al. Endogenous nitric oxide synthase inhibitor: a novel marker of angiogenesis.

Tsurumi Y , Murohara T, Krasinski K et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Moncada S , Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology.

Pharmacol Rev. Konda S , Asano M, Matsuo K et al. Belgore FM , Lip GYH, Wadley M et al. Plasma levelsof vascular endothelial cell growth factor VEGF andits receptor sFlt-1 in haematological cancers: a comparison with breast cancer.

Am J Haematol. Kotch LE , Iyer NV, Laughner E et al. Defective vascularization of HIF-lalpha-null embryos is not associated with VEGF deficiency but with mesenchymal cell death.

Sone H , Kawakami Y, Okuda Y et al. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulation by acute glucose deprivationin cultured bovine retinal pigmented epithelial cells.

Satake S , Kuzuya M, Miura H et al. Up-regulation of vascular endothelial growth factor in response to glucose deprivation. Biol Chem. Park SH , Kim KW, Lee YS et al. Int J Mol Med. Cha DR , Kim NH, Yoon JW et al. Role of vascular endothelial growth factor in diabetic nephropathy.

Kim NH , Jung HH, Cha DR et al. Expression of vascular endothelial growth factor in response to high glucose in rat mesangial cells. J Endocrinol. Hoshi S , Nomoto Ki K, Kuromitsu J. High glucose induced VEGF expression via PKC and ERK in glomerular podocytes.

Aiello LP , Avery RL, Arrigg PG et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. Breier G , Damert A, Plate KH et al. Angiogenesis in embryos and ischemic disease. Gale NW , Yancopoulos GD. Growth factors acting viaendothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development.

Gene Dev. Carmeliet P , Ferrera V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Ferrara N , Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene.

Molica S , Vitelli G, Levato D et al. Increased serum levels of vascular endothelial growth factor predict risk of progression in early B-cell chronic lymphocytic leukaemia.

Br J Haematol. Zhang H-T , Craft P, Scott PAE et al. Enhancement of tumour growth and vascular dentistry by transfection of vascular endothelial cell growth factor into MCF-7 human breast carcinoma cells. J Natl Cancer Inst. Relf M , LeJeune S, Scott PA et al. Expression of the angiogenic factors VEGF, acidic and basic FGF, tumour growth factor beta-1, PDGF, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis.

Suzuki K , Hayashi N, Miyamoto Y et al. Viglietto G , Romano A, Maglione D et al. Neovascularisation in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not placenta-derived growth factor.

Viglietto G , Maglione D, Rambaldi M et al. Upregulation of vascular endothelial growth factor VEGF and down regulation of placenta growth factor PIGF associated with malignancy in human thyroid tumors and cell lines. Tsurusaki T , Kanda S, Sakai H et al.

Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis.

Br J Cancer. Salven P , Lymboussaki A, Heikkila P et al. Vascular endothelial growth factor VEGF-B and VEGF-C are expressed in human tumours. Soker S , Fidder H, Neufeld G et al. Characterization of novel endothelial growth factor VEGF receptors ontumour cells that bind VEGF via exon 7-encoded domain.

Faller DV. Endothelial cell responses to hypoxic stress. Clin Exp Pharmacol Physiol. Blann AD , Li J-L, Kumar S. Increased VEGF in 13 children with Wilms' tumour falls after surgery but rising levels predict mortality.

Cancer Lett. Ausprunk DH , Folkman J. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis. Lauer G , Sollberg S, Cole M et al. Expression and proteolysis of vascular endothelial growth factor increased in chronic wounds.

J Invest Dermatol. Mochida S , Ishikawa K, Inao M et al. Detmar M , Brown LF, Berse B et al. J Invest Derm. Lee SS , Joo YS, Kim WU et al. Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis.

Clin Exp Rheumatol. Robak E , Wozniacka A, Sysa-Jedrzejowska A et al. Serum levels of angiogenic cytokines in systemic lupus erythematosus and their correlation with disease activity. EurCytokine Netw. Mohle R , Green D, Moore MAS et al.

Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Fava RA , Olsen NJ, Spencer-Green G et al. Nagashima M , Yoshino S, Ishiwata T et al.

Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. J Rheumatol. Latour F , Zabraniecki L, Fromer C et al. Does vascular endothelial growth factor in the rheumatoid synovium predict joint destruction?

A clinical, radiological and pathological study in 12 patients monitored for 10 years. Joint Bone Spine. Paavonen K , Mandelin J, Partanen T et al. Vascular endothelial growth factors C and D and their VEGFR-2 and 3 receptors in blood and lymphatic vessels in healthy and arthritic synovium.

Li J , Brown LF, Hibberd MG et al. VEGF, flk-1, and flt-1 expression in a rat myocardial infarction model of angiogenesis. Hausner EA , Orsini JA, Foster LL et al. Vascular endothelial growth factor in porcine coronary arteries followingballoon angioplasty.

J Invest Surg. Ruef J , Hu ZY, Yin LY et al. Induction of vascular endothelial growth factor in balloon-injured baboon arteries. A novel role for reactive oxygen species in atherosclerosis. Harada K , Friedman M, Lopez JJ et al. Vascular endothelial growth factor administration in chronic myocardial ischaemia.

Lee SH , Wolf PL, Escudero et al. Early expression of angiogenesis factors in acute myocardial ischemia and infarction. Inoue M , Itoh H, Ueda M et al.

Vascular endothelial growth factor VEGF expression in human coronary atherosclerotic lesions. Possible pathophysiological significance of VEGF in the progression of atherosclerosis. Chen YX , Nakashima Y, Tenaka K et al. Couffinhal C , Kearney M, Witzenbichler B et al.

Bobryshev YV , Farnsworth AE, Lord RS. Expression of vascular endothelial growth factor in aortocoronary saphenous vein bypass grafts.

Cardiovasc Surg. Fleisch M , Billinger M, Eberli FR et al. Physiologically assessed coronary collateral flow and intra-coronary growth factor concentrations in patients with 1- to 3-vessel coronary artery disease. Burton PBJ , Owen VJ, Hafizi S et al. Hojo Y , Ikeda U, Zhu Y et al. Expression of vascular endothelial growth factor in patients with acute myocardial infarction.

J Am Coll Cardiol. Roller RE , Renner W, Tischler R et al. Vascular endothelial growth factor in plasma of patients undergoing peripheral angioplasty. O'Brien KD , Chait A.

The biology of the artery wall in atherogenesis. Med Clin North Am. Barger AC , Beeuwkes R, Lainey LL et al. Hypothesis: vasa vasorum and noevascularisation of human coronaryarteries.

A possible role in the Pathophysiology of atherosclerosis. Reyer JA , Myers PC, Appleberg M. Carotid intraplaque hemorrhage: the significance of neovascularity. J Vasc Surg. Henry TD. Therapeutic angiogenesis. Br Med J. Angiogenic therapy of the heart. Angiogenic therapy of the ischaemic limb. Helisch A , Ware JA.

Therapeutic angiogenesis in ischemic heart disease. Kornowski R , Fuchs S, Leon MB et al. Delivery strategies to achieve therapeutic myocardial angiogenesis. Henry TD , Rocha-Singh K, Isner JM et al. Intra-coronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease.

Rosengart TK , Lee LY, Patel SR et al. Phase 1 asessment of direct intramyocardial administration of an adenovirisexpressing VEGF cDNA to individuals with clinically significant severe coronary artery disease. Isner JM , Pieczek A, Schainfeld R et al.

Clinical evidence of angiogenesis after arterial gene transfer of phVEGF in paitent with ischaemic limb. Celletti FL , Waugh JM, Amabile PG et al. Vascular endothelial growth factor enhances atherosclerotic plaque progression.

Brenchley PEC. Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis. Braybrooke JP , O'Byrne K, Propper DJ et al. A phase II study of Razoxane, an anti-angiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Clin Cancer Res. Lederman RJ , Mendelsohn FO, Anderson RD et al. for the TRAFFIC Investigators. Therapeutic angiogenesis with recombinant fibroblastic growth factor-2 for intermittent claudication the TRAFFIC study : a randomized trial.

Oxford University Press is a department of the University of Oxford. It furthers the University's objective of excellence in research, scholarship, and education by publishing worldwide. Sign In or Create an Account. Advertisement intended for healthcare professionals.

Navbar Search Filter European Heart Journal This issue ESC Publications Cardiovascular Medicine Books Journals Oxford Academic Mobile Enter search term Search. Issues More Content Advance Articles Editor's Choice Braunwald's Corner ESC Guidelines EHJ Dialogues Issue a Glance Podcasts CardioPulse Weekly Journal Scan European Heart Journal Supplements Year in Cardiovascular Medicine Asia in EHJ Most Cited Articles ESC Content Collections Submit Author Guidelines Submission Site Why publish with EHJ?

ESC Publications. Advanced Search. Search Menu. Article Navigation. Close mobile search navigation Article Navigation. Volume Article Contents 1 Introduction. Journal Article. Angiogenesis: basic pathophysiology and implications for disease.

C Felmeden , D. C Felmeden. Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. lip bham. Oxford Academic. Google Scholar. D Blann. H Lip. Revision received:. PDF Split View Views.

Cite Cite D. Select Format Select format. ris Mendeley, Papers, Zotero. enw EndNote. bibtex BibTex. txt Medlars, RefWorks Download citation. Permissions Icon Permissions. Close Navbar Search Filter European Heart Journal This issue ESC Publications Cardiovascular Medicine Books Journals Oxford Academic Enter search term Search.

Angiogenesis , Vasculogenesis , Vascular endothelial growth factor , Fibroblast growth factor , Angiopoietin. Table 1 Key events of angiogenesis. Key events.

Endothelial cell and pericyte activation Morphological changes of endothelial cells priming them for proliferation and secretion, local vasodilatation, increased vascular permeability, accumulation of extravascular fibrin Degradation of basement membrane Angiogenic stimulus results in proteolytic vascular basement membrane degradation Migration of endothelial cells Chemotactic factors produced by fibroblasts, monocytes and platelets induce endothelial cell migration and sprouting Proliferation of endothelial cells Locally produced mitogens induce endothelial cells DNA synthesis and mitosis Differentiation of endothelial cells Endothelial cell proliferation decreases and cell—cell contact re-establish, sprout develops lumen Reconstitution of basement membrane Vessel maturation achieved by reconstitution of basement membrane synthesized by endothelial cells and pericytes Vasculature maturation and stabilization Capillary remodelling by stabilization and regression.

Open in new tab. Table 2 Phenotypes of transgenic mice with embryonic defects in vascular development. Affected gene. Stage of vessel development. Detected phenotype. VEGF-A Vasculogenesis and angiogenesis Malformation of dorsal aorta, defective heart and vessel sprouting.

Vascular endothelial growth factor-A VEGF is the fundamental regulator of vascular growth and the key target of therapeutic angiogenesis approaches.

However, first-generation clinical trials of VEGF gene therapy have been disappointing, and a clear clinical benefit has yet to be established. In particular, VEGF delivery a appears to have a very limited therapeutic window in vivo: low doses are safe but mostly inefficient, whereas higher doses become rapidly unsafe; and b requires a sustained expression in vivo of at least about four weeks to achieve stable vessels that persist after cessation of the angiogenic stimulus.

Here we will review the current understanding of how VEGF induces the growth of normal or pathological blood vessels, what limitations for the controlled induction of safe and efficient angiogenesis are intrinsically linked to the biological properties of VEGF, and how this knowledge can guide the design of more effective strategies for therapeutic angiogenesis.

Login Register. Forgot your password? Skip to main navigation menu Skip to main content Skip to site footer. Fulltext PDF Fulltext HTML.

Angiogenesis and vascular growth major advances in medical, catheter-based anx surgical treatment, cardiovascular diseases techniques for insulin management Angiogenesis and vascular growth peripheral vascula disease and coronary artery disease still Angioyenesis significant morbidity and mortality. Furthermore, many patients do not qualify Angiogenesis and vascular growth catheter-based treatment or vawcular surgery because of advanced disease or surgical risk. There Agniogenesis therefore an urgent need for novel treatment strategies. Therapeutic angiogenesis aims to restore blood flow to ischaemic tissue by stimulating the growth of new blood vessels through the local delivery of angiogenic factors, and may thus be an attractive treatment alternative for these patients. Angiogenesis is a complex process and the growth of normal, stable and functional vasculature depends on the coordinated interplay of different cell types and growth factors. Vascular endothelial growth factor-A VEGF is the fundamental regulator of vascular growth and the key target of therapeutic angiogenesis approaches. However, first-generation clinical trials of VEGF gene therapy have been disappointing, and a clear clinical benefit has yet to be established.